MIR-21-5P DRIVES NASH-ASSOCIATED HEPATOCARCINOGENESIS

Pedro M. Rodrigues  1, 2, 3     Marta Bento Afonso  1     André Lopes Simão  1     Tawhidul Islam  1     Maria Manuela Gaspar  1     Colm J. O’Rourke  4     Monika Lewinska  4     Jesper B. Andersen  4     Enara Arretxe  5     Cristina Alonso  5     Álvaro Santos-Laso  2     Laura Izquierdo-Sanchez  1, 2     Raúl Jimenez-Agüero  2     Emma Eizaguirre  2     Luis Bujanda  2, 6     Maria J. Pareja  7     Carina Prip-Buus  8     Jesús M. Bañales  2, 6, 9     Cecília Maria Pereira Rodrigues  1     Rui Castro  1    
1 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
2 Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
3 Centre for the Study of Liver and Gastro
4 Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5 OWL Metabolomics, Derio, Spain
6 Centre for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain
7 Hospital Juan Ramón Jiménez, Huelva, Spain
8 Université Paris Descartes UMR-S 1016, Institut Cochin, Paris, France
9 IKERBASQUE, Basque Found

Topic
Colorectal, Digestive Oncology, Hepatobiliary, Mechanisms & Personalised Medicine, Pancreas

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing